Literature DB >> 29654002

Stopping β-Blockers After Myocardial Infarction: Not So Fast!

Dennis T Ko1, Cynthia A Jackevicius2.   

Abstract

Entities:  

Keywords:  Editorials; medication adherence; meta-analysis; mortality; myocardial infarction

Mesh：

Substances：

Year:  2018        PMID： 29654002     DOI： 10.1161/CIRCOUTCOMES.118.004678

Source DB:  PubMed          Journal:  Circ Cardiovasc Qual Outcomes        ISSN： 1941-7713


× No keyword cloud information.
  4 in total

1.  β-blockers after myocardial infarction and 1-year clinical outcome - a retrospective study.

Authors:  Tora Hagsund; Sven-Erik Olsson; J Gustav Smith; Bjarne Madsen Hardig; Henrik Wagner
Journal:  BMC Cardiovasc Disord       Date:  2020-04-09       Impact factor: 2.298

2.  The Hypertension Paradox: Survival Benefit After ST-Elevation Myocardial Infarction in Patients With History of Hypertension. A Prospective Cohort- and Risk-Analysis.

Authors:  Fabian Hoffmann; Patricia Fassbender; Wilhelm Zander; Lisa Ulbrich; Kathrin Kuhr; Christoph Adler; Marcel Halbach; Hannes Reuter
Journal:  Front Cardiovasc Med       Date:  2022-02-24

3.  The duration of beta-blocker therapy and outcomes in patients without heart failure or left ventricular systolic dysfunction after acute myocardial infarction: A multicenter prospective cohort study.

Authors:  Xue-Song Wen; Rui Luo; Jie Liu; Zhi-Qiang Liu; Han-Wen Zhang; Wei-Wei Hu; Qin Duan; Shu Qin; Jun Xiao; Dong-Ying Zhang
Journal:  Clin Cardiol       Date:  2022-03-04       Impact factor: 3.287

4.  Cardiolipin remodeling by ALCAT1 links hypoxia to coronary artery disease by promoting mitochondrial dysfunction.

Authors:  Dandan Jia; Jun Zhang; Jia Nie; John-Paul Andersen; Samantha Rendon; Yue Zheng; Xueling Liu; Zhenjun Tian; Yuguang Shi
Journal:  Mol Ther       Date:  2021-06-08       Impact factor: 11.454
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.